机构：[1]Henan Key Laboratory of Cancer Epigenetics Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China[2]Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China[3]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China[4]Medical College, Henan University of Science and Technology, Luoyang 471003, Henan, China[5]Department of Image Diagnoses, The First Affiliated Hospital, and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China[6]Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, USA
Various genetic polymorphisms have been linked to lung cancer susceptibility and survival outcomes. Vitamin D (VD) regulates cell proliferation and differentiation, inhibits tumor growth and induces apoptosis. Observations from several previous studies including our own suggest that genetic polymorphisms in the VD pathway may be associated with lung cancer risk. The aim of this study is to assess if genetic polymorphisms in the VD pathway are associated with the prognosis of non-small cell lung cancer (NSCLC). Nine single nucleotide polymorphisms (SNPs) in five genes in the VD pathway were genotyped with the TaqMan assays in 542 patients with primary NSCLC, and the relationships between these SNPs and overall survival were evaluated. We found that SNP rs10741657 in the CYP2R1 gene was associated with the prognosis of NSCLC, especially in elderly patients and not being treated with chemotherapy. Some of the VD pathway-related genetic polymorphisms may influence the prognosis of NSCLC. More research is needed to further confirm the finding and test if VD supplements can be used for NSCLC treatment.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573231]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [15ZR1424400]; Translational Medicine Foundation of SJTU medical college [15ZH1001]; Medical and Health Project of Luoyang Science and Technology [1603001A-5]
第一作者机构：[1]Henan Key Laboratory of Cancer Epigenetics Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China[2]Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China[3]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Kong Jinyu,Chen Xiaojie,Wang Jian,et al.Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival[J].PATHOLOGY & ONCOLOGY RESEARCH.2020,26(3):1709-1715.doi:10.1007/s12253-019-00702-4.
APA：
Kong, Jinyu,Chen, Xiaojie,Wang, Jian,Li, Jingxin,Xu, Fangxiu...&Qian, Biyun.(2020).Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival.PATHOLOGY & ONCOLOGY RESEARCH,26,(3)
MLA：
Kong, Jinyu,et al."Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival".PATHOLOGY & ONCOLOGY RESEARCH 26..3(2020):1709-1715
